Clear Search

Showing 16 results for “long-term”.

January 2024

Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature

Lupus Sci Med. 2023; 10(2):e001032 DOI: 10.1136/lupus-2023-001032

This study from Arnaud et al described baseline characteristics of SLE patients grouped by disease activity and IFNGS category in the international SPOCS study. IFNGS-high patients were younger at SLE diagnosis, and a baseline SLEDAI-2K score ≥10 was associated with shorter disease duration, more frequent and more severe flares. IFNGS-low patients were more likely to exhibit musculoskeletal and CNS comorbidities than IFNGS-high patients. Continuation of the SPOCS study will allow investigation into how different baseline characteristics affect long-term outcomes in SLE patients.

more…

December 2023

Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial

Arthritis Rheumatol. 2023 DOI 10.1002/art.42734

This post hoc analysis of the Phase 2 NOBILITY trial determined that obinutuzumab plus standard of care improved the likelihood of long-term preservation of kidney function and improved kidney function with less glucocorticoid use in patients with lupus nephritis.

more…

August 2023
June 2023

Remission of Lupus Nephritis: The Trajectory of Histological Response in Successfully Treated Patients

Lupus Sci Med. 2023;10(1):e000932 doi: 10.1136/lupus-2023-000932

LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression.

more…

February 2023
December 2022

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42392

Long-term extension study shows an acceptable long-term safety profile of anifrolumab in SLE, in addition to sustained improvements in disease activity and reduction in glucocorticoid use.

more…

May 2022

Impact of belimumab on organ damage in systemic lupus erythematosus

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901

Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.

more…

March 2022

Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis

Kidney Int Rep. 2021;7(3):516–25

Analysis of 22 patients with lupus nephritis (LN) demonstrates that triple immunosuppression with the addition of tacrolimus to mycophenolate and prednisolone results in further proteinuria reduction.

more…

January 2022